The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rollins, S. A.
Right arrow Articles by Sims, P. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rollins, S. A.
Right arrow Articles by Sims, P. J.

The Journal of Immunology, Vol 144, Issue 9 3478-3483, Copyright © 1990 by American Association of Immunologists

ARTICLES

The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9

SA Rollins and PJ Sims
Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City 73104.

A human E membrane protein that inhibits lysis by the purified human C5b-9 proteins was isolated and characterized. After final purification, the protein migrated as an 18- to 20-kDa band by SDS- PAGE. Elution from gel slices and functional assay after SDS-PAGE (nonreduced) confirmed that all C5b-9 inhibitory activity of the purified protein resided in the 18- to 20-kDa band. Phosphatidylinositol-specific phospholipase C digestion of the purified protein abolished 50% of its C5b-9 inhibitory activity, and removed approximately 15% of the protein from human E. Western blots of normal and paroxysmal nocturnal hemoglobinuria E revealed an absence of the 18- to 20-kDa protein in the paroxysmal nocturnal hemoglobinuria E cells. The identity of this E protein with leukocyte Ag CD59 (P18, HRF20) was confirmed immunochemically and by N-terminal amino acid sequence analysis. A blocking antibody raised against the purified protein reacted with a single 18- to 20-kDa band on Western blots of human erythrocyte membranes. Prior incubation of human E with the F(ab) of this antibody increased subsequent lysis by the purified human C5b-9 proteins. Potentiation of C5b-9-mediated lysis was observed when erythrocytes were preincubated with this blocking antibody before C5b-9 assembly was initiated, or, when this antibody was added after 30 min, 0 degrees C incubation of C5b-8-treated E with C9. Chicken E incubated with purified CD59 were used to further characterize the mechanism of its C-inhibitory activity. Preincorporation of CD59 into these cells inhibited lysis by C5b-9, regardless of whether CD59 was added before or after assembly of the C5b-8 complex. When incorporated into the membrane, CD59 inhibited binding of 125I-C9 to membrane C5b-8 and reduced the extent of formation of SDS-resistant C9 polymer. The inhibitory effect of CD59 on 125I-C9 incorporation was most pronounced at near-saturating input of C9 (to C5b-8). By contrast, CD59 did not inhibit either C5b67 deposition onto the cell surface, or, binding of 125I-C8 to preassembled membrane C5b67. Taken together, these data suggest that CD59 exerts its C-inhibitory activity by limiting incorporation of multiple C9 into the membrane C5b-9 complex.


This article has been cited by other articles:


Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
S. Yun, V. W.Y. Leung, M. Botto, J. J. Boyle, and D. O. Haskard
Brief Report: Accelerated Atherosclerosis in Low-Density Lipoprotein Receptor-Deficient Mice Lacking the Membrane-Bound Complement Regulator CD59
Arterioscler. Thromb. Vasc. Biol., October 1, 2008; 28(10): 1714 - 1716.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
K. Ramo, S. M. Cashman, and R. Kumar-Singh
Evaluation of Adenovirus-Delivered Human CD59 as a Potential Therapy for AMD in a Model of Human Membrane Attack Complex Formation on Murine RPE
Invest. Ophthalmol. Vis. Sci., September 1, 2008; 49(9): 4126 - 4136.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
D. D. Kim, T. Miwa, Y. Kimura, R. A. Schwendener, M. van Lookeren Campagne, and W.-C. Song
Deficiency of decay-accelerating factor and complement receptor 1-related gene/protein y on murine platelets leads to complement-dependent clearance by the macrophage phagocytic receptor CRIg
Blood, August 15, 2008; 112(4): 1109 - 1119.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
R. A. Brodsky
Narrative Review: Paroxysmal Nocturnal Hemoglobinuria: The Physiology of Complement-Related Hemolytic Anemia
Ann Intern Med, April 15, 2008; 148(8): 587 - 595.
[Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
C. E. Soltani, E. M. Hotze, A. E. Johnson, and R. K. Tweten
Structural elements of the cholesterol-dependent cytolysins that are responsible for their cholesterol-sensitive membrane interactions
PNAS, December 18, 2007; 104(51): 20226 - 20231.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
D. D. Kim, T. Miwa, and W.-C. Song
Retrovirus-Mediated Over-Expression of Decay-Accelerating Factor Rescues Crry-Deficient Erythrocytes from Acute Alternative Pathway Complement Attack
J. Immunol., October 15, 2006; 177(8): 5558 - 5566.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
P. Hillmen, N. S. Young, J. Schubert, R. A. Brodsky, G. Socie, P. Muus, A. Roth, J. Szer, M. O. Elebute, R. Nakamura, et al.
The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.
N. Engl. J. Med., September 21, 2006; 355(12): 1233 - 1243.
[Abstract] [Full Text] [PDF]

Home page
 ScienceHome page
J. P. Brockes and A. Kumar
Appendage Regeneration in Adult Vertebrates and Implications for Regenerative Medicine
Science, December 23, 2005; 310(5756): 1919 - 1923.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Hill, P. Hillmen, S. J. Richards, D. Elebute, J. C. Marsh, J. Chan, C. F. Mojcik, and R. P. Rother
Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria
Blood, October 1, 2005; 106(7): 2559 - 2565.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
P. Hillmen, C. Hall, J. C.W. Marsh, M. Elebute, M. P. Bombara, B. E. Petro, M. J. Cullen, S. J. Richards, S. A. Rollins, C. F. Mojcik, et al.
Effect of Eculizumab on Hemolysis and Transfusion Requirements in Patients with Paroxysmal Nocturnal Hemoglobinuria
N. Engl. J. Med., February 5, 2004; 350(6): 552 - 559.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
I. Ghiran, L. B. Klickstein, and A. Nicholson-Weller
Calreticulin Is at the Surface of Circulating Neutrophils and Uses CD59 as an Adaptor Molecule
J. Biol. Chem., May 30, 2003; 278(23): 21024 - 21031.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
D. L. Pflugh, S. E. Maher, and A. L. M. Bothwell
Ly-6 Superfamily Members Ly-6A/E, Ly-6C, and Ly-6I Recognize Two Potential Ligands Expressed by B Lymphocytes
J. Immunol., November 1, 2002; 169(9): 5130 - 5136.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. Miwa, L. Zhou, B. Hilliard, H. Molina, and W.-C. Song
Crry, but not CD59 and DAF, is indispensable for murine erythrocyte protection in vivo from spontaneous complement attack
Blood, May 15, 2002; 99(10): 3707 - 3716.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. A. Caragine, N. Okada, A. B. Frey, and S. Tomlinson
A Tumor-expressed Inhibitor of the Early but not Late Complement Lytic Pathway Enhances Tumor Growth in a Rat Model of Human Breast Cancer
Cancer Res., February 1, 2002; 62(4): 1110 - 1115.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
Y.-M. Qian, X. Qin, T. Miwa, X. Sun, J. A. Halperin, and W.-C. Song
Identification and Functional Characterization of a New Gene Encoding the Mouse Terminal Complement Inhibitor CD59
J. Immunol., September 1, 2000; 165(5): 2528 - 2534.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
D. L. Pflugh, S. E. Maher, and A. L. M. Bothwell
Ly-6I, a New Member of the Murine Ly-6 Superfamily with a Distinct Pattern of Expression
J. Immunol., July 1, 2000; 165(1): 313 - 321.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
H.-f. Zhang, J. Yu, S. Chen, B. P. Morgan, R. Abagyan, and S. Tomlinson
Identification of the Individual Residues That Determine Human CD59 Species Selective Activity
J. Biol. Chem., April 16, 1999; 274(16): 10969 - 10974.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. Tone, L. E. Diamond, L. A. Walsh, Y. Tone, S. A. J. Thompson, E. M. Shanahan, J. S. Logan, and H. Waldmann
High Level Transcription of the Complement Regulatory Protein CD59 Requires an Enhancer Located in Intron 1
J. Biol. Chem., January 8, 1999; 274(2): 710 - 716.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
R. Rautemaa, G. A. Jarvis, P. Marnila, and S. Meri
Acquired Resistance of Escherichia coli to Complement Lysis by Binding of Glycophosphoinositol-Anchored Protectin (CD59)
Infect. Immun., May 1, 1998; 66(5): 1928 - 1933.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
X.-j. Zhao, J. Zhao, Q. Zhou, and P. J. Sims
Identity of the Residues Responsible for the Species-restricted Complement Inhibitory Function of Human CD59
J. Biol. Chem., April 24, 1998; 273(17): 10665 - 10671.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
A E Berstad and P Brandtzaeg
Expression of cell membrane complement regulatory glycoproteins along the normal and diseased human gastrointestinal tract
Gut, April 1, 1998; 42(4): 522 - 529.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
J. Yu, R. Abagyan, S. Dong, A. Gilbert, V. Nussenzweig, and S. Tomlinson
Mapping the Active Site of CD59
J. Exp. Med., February 17, 1997; 185(4): 745 - 754.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
D. L. Bodian, S. J. Davis, B. P. Morgan, and N. K. Rushmere
Mutational Analysis of the Active Site and Antibody Epitopes of the Complement-inhibitory Glycoprotein, CD59
J. Exp. Med., February 3, 1997; 185(3): 507 - 516.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
R. P. Rother, J. Zhao, Q. Zhou, and P. J. Sims
Elimination of Potential Sites of Glycosylation Fails to Abrogate Complement Regulatory Function of Cell Surface CD59
J. Biol. Chem., September 27, 1996; 271(39): 23842 - 23845.
[Abstract] [Full Text] [PDF]

Home page
 JDRHome page
R. Rautemaa and S. Meri
Protection of Gingival Epithelium against Complement-mediated Damage by Strong Expression of the Membrane Attack Complex Inhibitor Protectin (CD59)
Journal of Dental Research, January 1, 1996; 75(1): 568 - 574.
[Abstract] [PDF]

Home page
 J. Biol. Chem.Home page
D. H. Lockert, K. M. Kaufman, C.-P. Chang, T. Hüsler, J. M. Sodetz, and P. J. Sims
Identity of the Segment of Human Complement C8 Recognized by Complement Regulatory Protein CD59
J. Biol. Chem., August 25, 1995; 270(34): 19723 - 19728.
[Abstract] [Full Text] [PDF]

Home page
 ScienceHome page
D. Kooyman, G. Byrne, S McClellan, D Nielsen, M Tone, H Waldmann, T. Coffman, K. McCurry, J. Platt, and J. Logan
In vivo transfer of GPI-linked complement restriction factors from erythrocytes to the endothelium
Science, July 7, 1995; 269(5220): 89 - 92.
[Abstract] [PDF]

Home page
 J. Biol. Chem.Home page
T. Hüsler, D. H. Lockert, K. M. Kaufman, J. M. Sodetz, and P. J. Sims
Chimeras of Human Complement C9 Reveal the Site Recognized by Complement Regulatory Protein CD59
J. Biol. Chem., February 24, 1995; 270(8): 3483 - 3486.
[Abstract] [Full Text] [PDF]

Home page
 ScienceHome page
W. Hahn, E Menu, A. Bothwell, P. Sims, and B. Bierer
Overlapping but nonidentical binding sites on CD2 for CD58 and a second ligand CD59
Science, June 26, 1992; 256(5065): 1805 - 1807.
[Abstract] [PDF]

Home page
 J. Biol. Chem.Home page
H.-f. Zhang, S. Lu, S. L. Morrison, and S. Tomlinson
Targeting of Functional Antibody-Decay-accelerating Factor Fusion Proteins to a Cell Surface
J. Biol. Chem., July 13, 2001; 276(29): 27290 - 27295.
[Abstract] [Full Text] [PDF]

Home page
 J. Physiol.Home page
I. Farkas, L. Baranyi, Y. Ishikawa, N. Okada, C. Bohata, D. Budai, A. Fukuda, M. Imai, and H. Okada
CD59 blocks not only the insertion of C9 into MAC but inhibits ion channel formation by homologous C5b-8 as well as C5b-9
J. Physiol., March 1, 2002; 539(2): 537 - 545.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1990 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1990 by The American Association of Immunologists, Inc. All rights reserved.